Under investigation for its merger with Eos SENOLYTIX where Pulmatrix stockholders are expected to own only approximately 6% of the combined company, suggesting potentially unfavorable terms for existing shareholders.
Pulmatrix is acquiring Eos SENOLYTIX through a merger expected to close in Q3 2026, gaining access to a promising pipeline of gerotherapeutic candidates with strong preclinical data. The combined company will trade under ticker MTXL with merger-associated financings to support advancement through clinical milestones.
Articles that tag PULM but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
